Ausgabe 2/2023
Inhalt (14 Artikel)
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
Nurullah Akkoç, Carlos H. Arteaga, Simone E. Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, Philip J. Mease
Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
Wan-Hee Yoo, Young Mo Kang, Dong Wook Kim, Eun Ha Kang, Yeon-Ah Lee, Chang-Hee Suh, Yoon-Kyoung Sung, Sang-Hoon Lee, Dong-Ha Gu, Jiwon Lee, Jung-Yoon Choe
A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still’s Disease: A Single-Center Retrospective Observational Study
Shih-Hsin Chang, Teng-Chieh Hsu, Po-Hao Huang, Chien-Chung Huang, Kai-Jieh Yeo, Wei-Jhe Hong, Po-Ku Chen, Yun-Hsieh Lin, Joung-Liang Lan, Der-Yuan Chen
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Roy Fleischmann, Boulos Haraoui, Maya H. Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee
Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA
Wen-Nan Huang, Ching-Yi Chuo, Ching-Heng Lin, Yi-Ming Chen, Wei-Szu Lin, Katie Tuckwell, Nicholas S. Jones, Joshua Galanter, Lisa Lindsay
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Wenhui Xie, Hong Huang, Zhuoli Zhang
Number of Attending Physicians and Accumulated Organ Damage in Patients with Systemic Lupus Erythematosus: LUNA Registry Cross-Sectional Study
Ryo Yanai, Nobuyuki Yajima, Nao Oguro, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Yoshia Miyawaki, Ryusuke Yoshimi, Takashi Kida, Yusuke Matsuo, Keisuke Nishimura, Ken-ei Sada
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
Peter C. Taylor, Yuri Sanchez Gonzalez, Ryan Clark, Freddy Faccin, Oliver Howell
Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
Christopher F. Bell, Jake Chung, Bernard Rubin
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
Peter C. Taylor, Yun-Fei Chen, Janet Pope, Michael Weinblatt, Eduardo Mysler, Andrea Rubbert-Roth, Bochao Jia, Luna Sun, Yushi Liu, Thorsten Holzkämper, Yoshiya Tanaka
High Usability and Applicability Ratings for the New SmartClic®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study
Rieke Alten, Simon Moss, Stefanie Hahne, Angela T. Muriset, David Gruben, Mark Latymer
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
Stefan Siebert, Frank Behrens, Ennio Lubrano, Nicolas Martin, Mohamed Sharaf, Christine Contré, Elke Theander, Rubén Queiro, Miriam Zimmermann, Laure Gossec